MEDICINA
Departamento
Catholic University of the Sacred Heart
Milán, ItaliaPublicaciones en colaboración con investigadores/as de Catholic University of the Sacred Heart (27)
2024
-
Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022
eClinicalMedicine, Vol. 71
-
Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: A prospective study
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 1
-
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey
Infection
2023
-
Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings
International Journal of Infectious Diseases, Vol. 137, pp. 98-110
-
Empirical rescue treatment of Helicobacter pylori infection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry on H. pylori management (Hp-EuReg)
Gut, Vol. 72, Núm. 6, pp. 1054-1072
-
Procalcitonin and C-reactive protein to rule out early bacterial coinfection in COVID-19 critically ill patients
Intensive Care Medicine, Vol. 49, Núm. 8, pp. 934-945
-
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 15, pp. 2827-2842
-
Unmet Clinical Needs and Management Recommendations for Blastic Plasmacytoid Dendritic Cell Neoplasm: A Consensus-based Position Paper from an Ad Hoc International Expert Panel
HemaSphere, Vol. 7, Núm. 3, pp. E841
2022
-
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
Blood, Vol. 140, Núm. 26, pp. 2773-2787
-
COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP
Blood Advances, Vol. 6, Núm. 7, pp. 2427-2433
-
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
Leukemia, Vol. 36, Núm. 5, pp. 1371-1376
-
Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report
American Journal of Hematology
2021
-
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
Journal of Hematology and Oncology, Vol. 14, Núm. 1
-
Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results
Journal of Cancer Research and Clinical Oncology, Vol. 147, Núm. 2, pp. 619-631
-
Polymorphisms within the TNFSF4 and mapkapk2 loci influence the risk of developing invasive aspergillosis: A two-stage case control study in the context of the aspbiomics consortium
Journal of Fungi, Vol. 7, Núm. 1, pp. 1-17
-
Seasonal Human Coronavirus Respiratory Tract Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
The Journal of infectious diseases, Vol. 223, Núm. 9, pp. 1564-1575
-
Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome
Leukemia, Vol. 35, Núm. 6, pp. 1745-1750
2020
-
Host immune genetic variations influence the risk of developing acute myeloid leukaemia: results from the NuCLEAR consortium
Blood Cancer Journal, Vol. 10, Núm. 7
-
Polymorphisms within the ARNT2 and CX3CR1 genes are associated with the risk of developing invasive aspergillosis
Infection and Immunity, Vol. 88, Núm. 4
-
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
The Lancet Haematology, Vol. 7, Núm. 5, pp. e370-e380